Clinical Trials
33 trialsNCT05712278 2025-09-12
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
Sanofi
Phase 1 Terminated
NCT04526795 2024-12-12
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05601466 2024-11-06
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
NCT05601830 2024-11-06
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT04196010 2023-12-28
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
University of Washington
Phase 1 Terminated
NCT03904251 2023-11-18
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT02957032 2023-10-10
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Philogen S.p.A.
Phase 1 Terminated
NCT04402723 2022-12-01
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Terminated
NCT01187810 2022-03-31
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
Phase 1 Terminated
NCT03519984 2021-11-30
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
University of Southern California
Phase 1 Terminated
NCT02483000 2020-11-23
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT01636609 2020-04-13
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02109627 2020-03-24
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
University of California, San Francisco
Phase 1 Terminated
NCT03135028 2020-03-06
Japanese AML
Gilead Sciences
Phase 1 Terminated
NCT02875093 2020-03-05
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Polaris Group
Phase 1 Terminated
NCT02954653 2019-11-21
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
Phase 1 Terminated
NCT01408160 2019-09-06
Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Albert Einstein College of Medicine
Phase 1 Terminated
NCT03735446 2019-06-12
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01701323 2019-03-01
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Phase 1 Terminated
NCT00928200 2019-02-19
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT01849276 2019-01-31
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Northwestern University
Phase 1 Terminated
NCT02412475 2019-01-24
Epigenetic Reprogramming in Relapse AML
Medical College of Wisconsin
Phase 1 Terminated
NCT02676323 2018-11-14
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Phase 1 Terminated
NCT01904643 2018-10-29
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 1 Terminated
NCT00907517 2018-08-27
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02635074 2018-05-14
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 1 Terminated
NCT01801046 2018-03-30
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
University of Southern California
Phase 1 Terminated
NCT02049801 2017-12-06
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 1 Terminated
NCT02255162 2017-08-18
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
Massachusetts General Hospital
Phase 1 Terminated
NCT01027923 2015-01-26
AML
Washington University School of Medicine
Phase 1 Terminated
NCT00124644 2013-05-03
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01265199 2013-01-23
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Ascenta Therapeutics
Phase 1 Terminated